biopharmaceutical development News
-
Symic Bio to Present at the 10th Annual ChinaBio Partnering Forum
SAN FRANCISCO, April 18, 2018 – Symic Bio, a biopharmaceutical company developing novel extracellular matrix targeting drugs, today announced that Rinko Ghosh, President and Chief Business Officer, will present an overview of the company pipeline at the 10 thAnnual ChinaBio Partnering Forum being held April 25-26, 2018, in Suzhou, China. ...
-
Symic Bio to Present at the BioCentury 25th Annual Future Leaders Conference in New York
SAN FRANCISCO, March 15, 2018 – Symic Bio, a biopharmaceutical company developing novel extracellular matrix targeting drugs, today announced that Ken Horne, Chief Executive Officer, will present an overview of the company pipeline at the BioCentury 25 th Annual Future Leaders in the Biotech Industry Conference in New ...
-
GI Innovation sings MoU for a new biopharmaceutical development with Merck
-Accelerating for development of high expression cell line through combination of GI-SMARTTM platform technology of GI Innovation and CHOZN® Platform of Merck -Expecting synergy of both companies for biopharmaceutical development using CHOZN® Platform, supplying subsidiary materials, education consulting, and etc.,. GI Innovation Co., Ltd. announced that it signed MoU for a ...
-
Diffusion Pharmaceuticals to Participate in the Alliance Global Partners Biotech & Specialty Pharma Conference
Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, will participate in the 2021 Alliance Global Partners Biotech & Specialty Pharma Conference taking place November 10, 2021. Diffusion ...
By CervoMed
-
Scopus Biopharma Completes Recapitalization Designed To Enhance Shareholder Value
New York, New York, October 18, 2022 – Scopus BioPharma Inc. (Nasdaq: “SCPS”), a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, announced today the completion of a series of related recapitalization transactions designed to enhance shareholder value. These transactions include the elimination of ...
-
Enterome to present the significant potential of its Mimicry concept, platform and pipeline at BMO’s Biopharma Spotlight Series conference – Immunology and Inflammation
Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial effector-based drug discovery platform, announces that its CEO, Pierre Belichard, will present at the BMO Biopharma Spotlight Series conference on Immunology and Inflammation, which will take place virtually April 6, 2022. ...
By Enterome
-
Diffusion Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
Diffusion Pharmaceuticals Inc.(NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced that Robert Cobuzzi, Jr., Ph.D., the Company’s President and Chief Executive Officer, will be presenting at the H.C. Wainwright ...
By CervoMed
-
Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — to Present at the 3rd Annual STING & TLR-Targeting Therapies Summit
New York, New York, March 22, 2022 – Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, today announced that Alan Horsager, Ph.D., President and Chief Executive Officer of Duet BioTherapeutics, will present at the 3rd Annual STING & TLR-Targeting ...
-
Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — Announces Key Scientific Data to be Presented at the 37th Annual Meeting and Exposition of the Society for Immunotherapy of Cancer
New York, New York, November 10, 2022 – Scopus BioPharma Inc. (Nasdaq: “SCPS”), a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, and its pure-play immuno-oncology subsidiary, Duet BioTherapeutics, today announced that key scientific data will be will be presented at the 37th Annual Meeting and ...
-
Symic Bio Announces Last Patient Enrolled in Osteoarthritis Phase 2b Study MODIFY3
DENMARK & SAN FRANCISCO, October 8, 2020 – Symic Bio, a biopharmaceutical company developing novel extracellular matrix targeting drugs, today announced that the last patient had been enrolled in its Phase 2b OA (osteoarthritis) study. The study, dubbed MODIFY3, is a double-blinded, randomized controlled trial investigating Symic Bio’s DMOAD (diseasemodifying OA drug) candidate, ...
-
Scopus BioPharma Announces $9.75 Million Private Placement Priced At-The-Market
New York, New York, November 22, 2021 – Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, today announced it has entered into securities purchase agreements with certain institutional investors in connection with a private placement priced ...
-
Dynavax to Present at the H.C. Wainwright Global Investment Conference
Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that Ryan Spencer, Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference, being held May 23-26, 2022. The on demand presentation will be available, beginning Tuesday, May 24, 2022 at 7:00 a.m. E.T. ...
-
Dynavax to Present at the William Blair 42nd Annual Growth Stock Conference
Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that Ryan Spencer, Chief Executive Officer and Kelly MacDonald, Chief Financial Officer, will participate in a fireside chat during the William Blair 42nd Annual Growth Stock Conference in Chicago, Illinois on Monday June 6, 2022 at 4:40 ...
-
Dynavax to Present at the H.C. Wainwright Virtual BioConnect 2022 Conference
Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Ryan Spencer, Chief Executive Officer, will present at the H.C. Wainwright Virtual BioConnect 2022 Conference being held January 10-13, 2022. The on demand presentation will be available, beginning Monday, January 10, 2022 at 7:00 a.m. E.T. and may ...
-
Dynavax to Present at the Cowen 42nd Annual Health Care Conference
Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Ryan Spencer, Chief Executive Officer and Kelly MacDonald Chief Financial Officer, will participate in a virtual fireside chat at the Cowen 42nd Annual Health Care Conference on Wednesday, March 9, at 2:50 p.m. E.T. The presentation will be webcast ...
-
Enterome to present promising clinical progress on its OncoMimics™ pipeline and Mimicry Platform at Jefferies Healthcare Conference
Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug discovery platform, today announces that its CEO, Pierre Belichard, will provide a company update (in person) at the Jefferies Healthcare Conference in New York City, US which will take place June 8-10, 2022. In his presentation, Dr. Belichard will provide an ...
By Enterome
-
IMV Inc. Announces Strategic Reorganization
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX™ platform to treat solid and hematologic cancers, today announced a strategic reorganization together with the appointment of ...
By IMV Inc.
-
Enterome to present world first clinical data with EO2401, its first-in-class off-the-shelf OncoMimics™ therapeutic cancer vaccine, at ASCO 2022
Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug discovery platform, today announces that it will present for the first time proof-of-concept data from clinical trials with EO2401, its first-in-class off-the-shelf OncoMimics™ cancer immunotherapy at the American Society of Clinical Oncology (ASCO) ...
By Enterome
-
Dynavax to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 28, 2022
Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company focused on developing and commercializing innovative vaccines, will report fourth quarter and full year 2021 financial results on Monday, February 28, 2022, after the U.S. financial markets close. Dynavax will host a conference call and live audio webcast on Monday, February 28, 2022 at 4:30 p.m. ...
-
Symic Bio Selected for “The Best of The Liver Meeting 2018” at AASLD
SAN FRANCISCO, November 9, 2018 – Symic Bio, a biopharmaceutical company developing novel extracellular matrix targeting drugs, today announced that they were selected for “The Best of The Liver Meeting 2018” at the AASLD international liver meeting and will be presenting on its liver fibrosis program at the upcoming conference in San Francisco. Symic's molecule, SBR-294, is ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you